Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 4/20 | 0.41 |
| ▸ | GGPS1 | O95749 | 4/20 | 0.32 |
| ▸ | GBA1 | P04062 | 1/20 | 0.31 |
| ▸ | FDPS | P14324 | 1/20 | 0.31 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21789799 | 0.84 | — | — | |
| SCHEMBL21789873 | 0.81 | DNM1 (0.39) | DNM1GGPS1FDPSAGTR1OPRM1 | |
| SCHEMBL24387063 | 0.75 | DNM1 (0.43) | DNM1GGPS1 | |
| SCHEMBL10953399 | 0.74 | DNM1 (0.50) | DNM1GGPS1OPRM1 | |
| SCHEMBL21011624 | 0.74 | — | — | |
| SCHEMBL22035455 | 0.74 | — | — | |
| SCHEMBL25097532 | 0.73 | ALDH1A1 (0.37) | — | |
| SCHEMBL13642071 | 0.73 | MLYCD (0.31) | — | |
| SCHEMBL21240711 | 0.73 | DNM1 (0.33) | DNM1 | |
| SCHEMBL12570456 | 0.72 | DNM1 (0.40) | DNM1GGPS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11053253-B2 | Macrocyclic compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2021-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11053253-B2 | Macrocyclic compounds for treatment of medical disorders | CFD, TFPI, CFH | DNM1 3789/4885GGPS1 1439/4885GBA1 868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.